In a press release, Medtronic announced that it had received CE Mark clearance with the European Union for a new line of its Evera implantable cardioverter defibrillators. According to information from the company, the new devices offer better longevity, reduced skin pressure and a lower risk of shock.
In its press release, the company stated that the Evera ICD can function in a patient for up to 11 years after device implantation. This 11-year figure is 25 percent longer than survival times for other ICDs on the market. In addition, the Evera ICD is equipped with the company’s proprietary SmartShock technology. SmartShock helps reduce the number of unnecessary shocks a patient experiences.
Marshall Stanton is a VP at Medtronic. In prepared remarks, he said, "Patients suffering from debilitating heart rhythm disorders can rely on new treatment options that can significantly improve their quality of life, while adding peace of mind. Evera builds upon 20 years of leadership at Medtronic in driving product innovation and advancements in shock reduction therapy and device longevity.”
According to CEO Omar Ishrak, Medtronic wants to get at least 20 percent of its revenue from countries like India and China by 2016. He considers CE Mark clearance in the E.U. a stepping stone in that path.